← State exam

77. Pancreatic carcinoma

High yield

Ductal adenocarcinoma presents late with painless jaundice; staged by resectability on CT and treated with Whipple and chemotherapy.

Exam Prep · State examSurgery · HPBSurgery · Surgical oncology

1. Definition

  • Pancreatic carcinoma → malignant tumour of the exocrine pancreas; pancreatic ductal adenocarcinoma (PDAC) in about 90%
  • Periampullary tumours → arise within 1 cm of the ampulla of Vater: pancreatic head, ampulla, distal CBD, duodenum (pancreatic head is the most common and has the worst prognosis)
  • Other exocrine tumours → acinar cell carcinoma, colloid (mucinous) carcinoma from IPMN, adenosquamous, undifferentiated with osteoclast-like giant cells

2. Epidemiology

  • About 3% of cancers, but the 3rd–4th cause of cancer death in the West (expected to become 2nd)
  • Age → over 60 (peak 65–75); men slightly more
  • Location → head about 65–70%, body and tail 20–25%, diffuse 5–10%
  • At diagnosis → only 15–20% resectable, 30–35% locally advanced, 50% metastatic
  • 5-year survival about 10–12% for all patients; 20–30% after resection with adjuvant chemotherapy
  • Ampullary cancer → better prognosis (5-year survival 40–60% after resection; presents early with jaundice)

3. Aetiology and risk factors

  • Smoking → strongest modifiable risk (doubles the risk; about 25% of cases)
  • Age
  • Obesity, physical inactivity, high fat and red meat diet
  • Diabetes → long-standing type 2 is a risk; new-onset diabetes over 50 may be an early sign of the cancer
  • Chronic pancreatitis (especially hereditary)
  • Alcohol (heavy), via pancreatitis
  • Family history → 2 or more first-degree relatives (familial pancreatic cancer)
  • Genetic syndromes:
    • BRCA2 (and BRCA1, PALB2)
    • Peutz-Jeghers (STK11) → highest relative risk
    • Familial atypical multiple mole melanoma (CDKN2A / p16)
    • Lynch syndrome
    • Hereditary pancreatitis (PRSS1)
    • Familial adenomatous polyposis, ataxia-telangiectasia
  • Precursors → pancreatic intraepithelial neoplasia (PanIN), IPMN, MCN
  • Blood group non-O, H. pylori (weak)

4. Pathogenesis

  • PanIN progression → low grade to high grade to invasive cancer:
    • KRAS mutation → over 90% (early event)
    • CDKN2A (p16) loss → intermediate
    • TP53 and SMAD4 (DPC4) loss → late
  • Dense desmoplastic stroma → poor drug delivery, hypoxia; resistant to chemotherapy
  • Spread:
    • Local → CBD (jaundice), duodenum (obstruction, bleeding), portal vein and SMV, SMA, coeliac axis, perineural invasion (coeliac plexus → back pain)
    • Lymphatic → peripancreatic, hepatoduodenal ligament, coeliac, para-aortic nodes
    • Haematogenous → liver (most common), lung, bone
    • Peritoneum → ascites, Sister Mary Joseph nodule, Blumer's shelf
  • Body and tail tumours → no jaundice → found later, larger, more often metastatic

5. Classification

Histology

  • Ductal adenocarcinoma (90%) and variants
  • Acinar cell, colloid, adenosquamous, undifferentiated
  • (Neuroendocrine tumours → see question 78)

TNM 8th edition (by size)

  • T1 → ≤ 2 cm (T1a ≤ 0.5, T1b 0.5–1, T1c 1–2 cm)
  • T2 → > 2 and ≤ 4 cm
  • T3 → > 4 cm
  • T4 → involves coeliac axis, SMA or common hepatic artery (any size)
  • N1 → 1–3 nodes; N2 → 4 or more
  • M1 → distant metastases

Resectability (NCCN)

  • Resectable → no arterial contact (coeliac, SMA, common hepatic); no SMV or portal vein contact, or ≤ 180° without contour change
  • Borderline resectable:
    • SMV/portal vein → contact > 180°, or ≤ 180° with contour irregularity or thrombosis, reconstructable
    • SMA or coeliac → contact ≤ 180°
    • Common hepatic artery → short-segment contact, reconstructable
  • Locally advanced (unresectable) → SMA or coeliac contact > 180°; unreconstructable SMV/portal vein
  • Metastatic → liver, peritoneum, lung, distant nodes
Table of pancreatic cancer resectability on CT
Diagram: pancreatic cancer resectability and treatment for each stage

6. Clinical picture

Symptoms

  • Head tumours:
    • Painless progressive obstructive jaundice → dark urine, pale stools, itch
    • Weight loss, anorexia
    • Vague epigastric pain
    • Steatorrhoea (duct obstruction)
  • Body and tail tumours → epigastric pain radiating to the back (coeliac plexus invasion; worse lying flat, better leaning forward), marked weight loss; no jaundice until late (liver or hilar spread)
  • New-onset diabetes in an older, thin patient
  • Acute pancreatitis in an older patient without a cause
  • Vomiting (duodenal obstruction)
  • Depression, fatigue
  • Migratory thrombophlebitis (Trousseau's syndrome), DVT, pulmonary embolism

Signs

  • Jaundice, scratch marks
  • Palpable, non-tender gallbladder → Courvoisier's law (jaundice with a palpable gallbladder is unlikely to be from stones)
  • Hepatomegaly (metastases or obstruction)
  • Epigastric mass (advanced)
  • Virchow's node (Troisier's sign), Sister Mary Joseph nodule, ascites, Blumer's shelf
  • Cachexia
  • Splenomegaly → splenic vein thrombosis (body or tail)

7. Diagnosis

Blood tests

  • LFT → cholestatic (bilirubin, ALP, GGT)
  • CA 19-9 → raised in about 80%; not for screening or diagnosis alone; false positive in jaundice and cholangitis; negative in Lewis antigen-negative people (5–10%); useful for prognosis and follow-up
  • CEA, HbA1c, FBC, INR, albumin
  • Germline genetic testing for all patients (BRCA, PALB2, MMR → targeted treatment and family screening)

Imaging

  • Ultrasound → first test in jaundice: dilated ducts, mass, liver metastases
  • Pancreas-protocol multiphase CT (arterial and portal venous phases, thin slices) → key staging test: mass (hypodense), vessel contact, metastases; "double duct sign" (dilated CBD and pancreatic duct)
  • MRI with MRCP → small liver metastases, cystic lesions
  • EUS → small tumours, vessel involvement; EUS-guided FNA or core biopsy (before neoadjuvant therapy or for unresectable disease)
  • PET-CT → selected (borderline, high CA 19-9)
  • Staging laparoscopy → high CA 19-9, large or body-tail tumours, borderline disease (finds small peritoneal and liver deposits)
  • ERCP → biliary stent for cholangitis, severe jaundice, or delay before surgery (neoadjuvant therapy); brushings for cytology

Biopsy

  • Not required before resection of a typical resectable mass
  • Required before chemotherapy (neoadjuvant or palliative)

8. Differential diagnosis

  • Other periampullary cancers → ampullary, distal cholangiocarcinoma, duodenal
  • Chronic pancreatitis with an inflammatory mass
  • Autoimmune (IgG4) pancreatitis → "sausage-shaped" gland, IgG4 high, responds to steroids
  • Pancreatic neuroendocrine tumour (enhancing, slower)
  • Cystic neoplasms (IPMN, MCN)
  • Metastases to the pancreas (renal cell carcinoma), lymphoma
  • CBD stones, Mirizzi syndrome, benign biliary stricture
  • Peptic ulcer disease, gastric cancer

9. Treatment

Conservative

  • Multidisciplinary team decision for every patient
  • Adjuvant chemotherapy after resection (all fit patients, start within 12 weeks, 6 months):
    • Modified FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, fluorouracil) → fit patients; median survival about 54 months (PRODIGE 24)
    • Gemcitabine with capecitabine (ESPAC-4) → less fit
    • Gemcitabine alone → frail patients
  • Neoadjuvant therapy → borderline resectable and locally advanced tumours (FOLFIRINOX or gemcitabine with nab-paclitaxel ± chemoradiotherapy), then restage and resect if possible; increasingly used for resectable disease in trials
  • Metastatic or unresectable:
    • FOLFIRINOX or NALIRIFOX (fit), gemcitabine with nab-paclitaxel, gemcitabine alone (frail)
    • Olaparib maintenance in germline BRCA mutation
    • Pembrolizumab for MSI-high tumours (rare)
    • Median survival about 8–12 months
  • Palliation:
    • Jaundice → ERCP with self-expanding metal stent (first choice); PTBD if ERCP fails
    • Duodenal obstruction → duodenal stent or gastrojejunostomy (laparoscopic; better for longer survival)
    • Pain → opioids, EUS-guided coeliac plexus neurolysis, radiotherapy
    • Pancreatic enzyme replacement (Creon) → improves weight and survival
    • Thromboprophylaxis (high VTE risk), nutrition, palliative care, psychological support

Surgical

  • Only potential cure; candidate → resectable or responding borderline tumour, fit patient
  • Pancreaticoduodenectomy (Whipple) → head, uncinate and periampullary tumours:
    1. Assess for metastases (laparoscopy or laparotomy)
    2. Kocher manoeuvre; check the SMV/portal vein and SMA
    3. Cholecystectomy; divide the common hepatic duct
    4. Divide the gastroduodenal artery
    5. Divide the stomach (classic) or duodenum (pylorus-preserving)
    6. Divide the pancreas at the neck over the portal vein
    7. Divide the jejunum beyond the ligament of Treitz; dissect the uncinate process off the SMV and SMA (SMA margin)
    8. Remove the head, duodenum, distal CBD, gallbladder, ± antrum, and nodes
    9. Reconstruction (Child's) → pancreaticojejunostomy (or pancreaticogastrostomy), hepaticojejunostomy, gastro- or duodenojejunostomy
  • Venous resection (SMV/portal vein) with reconstruction → same survival as standard Whipple when needed for R0
  • Distal pancreatectomy with splenectomy → body and tail tumours; RAMPS (radical antegrade modular pancreatosplenectomy) for better posterior margins; Appleby procedure (with coeliac axis resection) in selected cases
  • Total pancreatectomy → diffuse tumour, positive neck margin, IPMN throughout the gland (causes brittle diabetes)
  • Minimally invasive (laparoscopic or robotic) → distal pancreatectomy widely; Whipple in expert centres
  • High-volume centres → lower mortality (under 3–5%)
  • Preoperative biliary drainage → not routine (more complications); only if cholangitis, very high bilirubin, or neoadjuvant therapy
  • Contraindications to resection → metastases (liver, peritoneal, distant nodes), arterial encasement > 180° (unless good response to neoadjuvant therapy), poor fitness
  • Surgical bypass (hepaticojejunostomy ± gastrojejunostomy) → unresectable disease found at laparotomy
Flowchart of the management of pancreatic cancer
Diagram: pancreatic cancer, from CT staging to surgery or palliation

10. Complications

Of the disease

  • Obstructive jaundice, cholangitis
  • Duodenal obstruction
  • Pain, cachexia
  • Venous thromboembolism, Trousseau's syndrome
  • Diabetes, malabsorption
  • Ascites, GI bleeding

Of the Whipple

  • Postoperative pancreatic fistula (10–30%; ISGPS grade B or C)
  • Delayed gastric emptying (most common; 15–30%)
  • Post-pancreatectomy haemorrhage → early (technical) or late (sentinel bleed from a pseudoaneurysm, gastroduodenal stump; angioembolisation)
  • Bile leak, chyle leak, intra-abdominal abscess
  • Marginal ulcer, diabetes, exocrine insufficiency
  • Mortality under 3–5% in high-volume centres; morbidity 30–50%

Mind map Pinch or scroll to zoom · drag to move

Show as a list

Pancreatic cancer

  • Risk
    • Smoking
    • Diabetes, obesity
    • Chronic pancreatitis
    • BRCA2, CDKN2A, PJS
    • PanIN, IPMN
  • Pathology
    • Ductal adenocarcinoma
    • KRAS > 90%
    • Head 65-70%
    • Perineural spread
  • Clinical
    • Painless jaundice
    • Courvoisier
    • Back pain: body, tail
    • New diabetes
    • Trousseau
  • Tests
    • Pancreas-protocol CT
    • Double duct sign
    • CA 19-9: follow-up
    • EUS biopsy
    • Staging laparoscopy
  • Stage
    • Resectable
    • Borderline
    • Locally advanced: SMA > 180
    • Metastatic
  • Treatment
    • Whipple
    • Distal pancreatectomy
    • mFOLFIRINOX adjuvant
    • Neoadjuvant: borderline
    • Metal stent, bypass

More in State exam